- Home
- CM vs GSK Comparison
CM vs GSK Comparison
Compare CM & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CM | GSK |
|---|---|---|
| Founded | 1867 | 1715 |
| Country | Canada | United Kingdom |
| Employees | N/A | 66841 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.3B | 108.7B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CM | GSK |
|---|---|---|
| Price | $108.34 | $48.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $107.50 | N/A |
| AVG Volume (30 Days) | 853.4K | ★ 3.2M |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | 2.75% | ★ 3.40% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.09 | $6.99 |
| Revenue Next Year | $4.65 | $4.19 |
| P/E Ratio | ★ $15.80 | $32.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $67.38 | $35.45 |
| 52 Week High | $117.05 | $61.70 |
Technical Indicators
Market Signals| Indicator | CM | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 32.67 |
| Support Level | $90.69 | $48.99 |
| Resistance Level | $113.28 | $49.15 |
| Average True Range (ATR) | 2.21 | 0.78 |
| MACD | -1.03 | 0.01 |
| Stochastic Oscillator | 22.79 | 12.01 |
Price Performance
Historical ComparisonAbout CM Canadian Imperial Bank of Commerce
Canadian Imperial Bank of Commerce is Canada's fifth-largest bank with over CAD 1.1 trillion in assets at the end of fiscal 2025. It operates four business segments: Canadian retail and business banking, Canadian commercial banking and wealth management, US commercial banking and wealth management, and capital markets. It serves approximately 14 million personal banking and business customers, primarily in Canada and the US.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.